Sodium-glucose co-transporter-2 inhibitors : a potential cardioprotective agent?

1 September 2024 (12:00 - 12:50)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Theodora Georgopoulou

Venizelio General Hospital, Heraklion (Greece)

9 More presentations in this session

Presentation thumbnail

Adverse Myocardial and vascular side effects of Immune Checkpoint Inhibitors: a prospective multimodal cardiovascular assessment (AMICI study)

Doctor M. Mirabel (Paris, FR)

Abstract Slides Video

Presentation thumbnail

Cardiovascular outcomes in acute coronary syndrome patients with cancer: a statewide population-linkage study

Doctor C. Yu (Toronto, CA)

Abstract Slides Video

Presentation thumbnail

The CTOX-Score, a clinical risk prediction tool for cardiovascular toxicity secondary to cancer therapies

Doctor J. Gonzalez Juanatey (Santiago de Compostela, ES)

Abstract Slides Video

Presentation thumbnail

Fibroblast activation in cardio-oncology

Doctor K. Loganath (Southampton, GB)

Abstract Slides Video

Presentation thumbnail

Disparities in diabetes-related outcomes in prostate cancer patients - role of social determinants of health and race

Doctor A. Guha (Augusta, US)

Abstract Slides Video

Access the full session

Session thumbnail

Cardio-oncology: predicting adverse effects and prognosis

The Event

Event poster

ESC Congress 2024

1 September 2024 12:00 CET

You may be interested in

Congress Presentation

SGLT2 inhibitors and cardiotoxicity in diabetic patients receiving anthracycline therapy: a retrospective study

Congress Presentation

Anthracycline cardiotoxicity in patients receiving sodium-glucose co-transporter-2 inhibitors -is there any difference?

Congress Presentation

The cardioprotective effect of inhibitor sodium glucose transporter in patients undergoing chemotherapy: a systematic review and meta-analysis

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources